These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25842814)

  • 21. Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.
    Anderegg MCJ; van der Sluis PC; Ruurda JP; Gisbertz SS; Hulshof MCCM; van Vulpen M; Mohammed NH; van Laarhoven HWM; Wiezer MJ; Los M; van Berge Henegouwen MI; van Hillegersberg R
    Ann Surg Oncol; 2017 Aug; 24(8):2282-2290. PubMed ID: 28424936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.
    Cartwright E; Cunningham D
    Curr Treat Options Oncol; 2017 Nov; 18(12):69. PubMed ID: 29143893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
    Kim SM; An JY; Lee J; Sohn TS; Kim S
    Ann Surg Oncol; 2018 Jun; 25(6):1616-1624. PubMed ID: 29569127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).
    Dikken JL; van Sandick JW; Maurits Swellengrebel HA; Lind PA; Putter H; Jansen EP; Boot H; van Grieken NC; van de Velde CJ; Verheij M; Cats A
    BMC Cancer; 2011 Aug; 11():329. PubMed ID: 21810227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy of advanced gastric cancer.
    Rivera F; Vega-Villegas ME; López-Brea MF
    Cancer Treat Rev; 2007 Jun; 33(4):315-24. PubMed ID: 17376598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D; Okines AF; Ashley S
    N Engl J Med; 2010 Mar; 362(9):858-9. PubMed ID: 20200397
    [No Abstract]   [Full Text] [Related]  

  • 27. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
    Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
    J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
    Li C; Wang X; Wang X; Han C; Wang P; Pang Q; Chen J; Sun X; Wang L; Zhang W; Lin Y; Ge X; Zhou Z; Ni W; Chang X; Liang J; Deng L; Wang W; Zhao Y; Xiao Z
    BMC Cancer; 2019 Apr; 19(1):397. PubMed ID: 31036088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A case of mediastinal lymph node gastric cancer recurrence during S-1 adjuvant therapy successfully treated with cisplatin + capecitabine as second-line chemotherapy].
    Hirata A; Itatsu K; Fukaya M; Ebata T; Yokoyama Y; Tsunoda N; Igami T; Sugawara G; Uehara K; Yoshioka Y; Usui H; Nagino M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):519-22. PubMed ID: 23848024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
    Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
    Al-Fakeeh A; Ferri L; Mulla N; Doerksen T; Al-Ruzug I; Santos F; Alcindor T
    Med Oncol; 2016 Jul; 33(7):62. PubMed ID: 27225939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial.
    Messager M; Mirabel X; Tresch E; Paumier A; Vendrely V; Dahan L; Glehen O; Vasseur F; Lacornerie T; Piessen G; El Hajbi F; Robb WB; Clisant S; Kramar A; Mariette C; Adenis A
    BMC Cancer; 2016 May; 16():318. PubMed ID: 27194176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Bölke E; Peiper M; Budach W
    N Engl J Med; 2008 May; 358(18):1965; author reply 1965. PubMed ID: 18450611
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment approaches to esophagogastric junction tumors.
    Kurokawa Y; Sasako M; Doki Y
    Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.